ADC Therapeutics SA reports results for the quarter ended in March - Earnings Summary

ADC Therapeutics SA

06/05/2024 13:00

* ADC Therapeutics SA  ADCT.N  reported a quarterly adjusted
loss
of 56 cents​​ per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -74 cents.  The mean expectation of six analysts for the
quarter was for a loss of 56 cents per share. Wall Street
expected results to range from -66 cents to -48 cents per share.
    * Revenue fell 4.9% to $18.05 million from a year ago;
analysts
expected $18.10 million. 
    * ADC Therapeutics SA's reported EPS for the quarter was a
loss
of 56 cents​.
    * The company reported a quarterly loss of $46.61 million.
    * ADC Therapeutics SA shares had risen by 9.1% this
quarter and
gained 195.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 17%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for ADC Therapeutics
SA is $10.00 
This summary was machine generated from LSEG data May 6 at 12:00
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.56          -0.56          Met
 Dec. 31 2023      -0.50          -1.03          Missed
 Sep. 30 2023      -0.63          -0.58          Beat
 Jun. 30 2023      -0.46          -0.58          Missed